Calcium Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Calcium dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Calcium.
Dosing Protocols
Beginner protocol (dietary adequacy for most adults). Aim for 1,000-1,200 mg/day total calcium from diet. A practical target: 2-3 servings of dairy per day (1 cup milk = ~300 mg, 1 cup yogurt = ~300-400 mg, 1.5 oz hard cheese = ~300 mg) or equivalent calcium-fortified plant milk, plus supplementation with leafy greens, tofu set with calcium sulfate, almonds, sardines, or calcium-fortified foods. No routine supplementation required if dietary intake is adequate.
For women aged 50+ and men aged 70+: RDA increases to 1,200 mg/day. If dietary intake is inadequate, supplement with 500-600 mg/day elemental calcium (from calcium carbonate or citrate) in divided doses with meals. Calcium carbonate 500 mg with breakfast and dinner, or calcium citrate 300 mg with each of 2-3 meals. Combine with vitamin D3 2,000-4,000 IU/day and vitamin K2 MK-7 100-180 μg/day.
For pregnancy and lactation: RDA 1,000 mg/day (unchanged from baseline). Prenatal vitamins typically provide 200-300 mg; diet supplies the rest. In low-calcium populations, WHO recommends 1.5-2 g/day supplementation for preeclampsia prevention.
Pediatric calcium: ensure age-appropriate intake from dairy, fortified foods, and calcium-containing vegetables. Supplementation beyond RDA is rarely needed in well-nourished children.
Intermediate protocol (osteoporosis prevention and mild deficiency). For postmenopausal women with osteopenia or DEXA T-score -1 to -2.5 without prior fragility fracture: calcium 500-600 mg/day supplemental (500 mg carbonate BID with meals, or 300 mg citrate with each of 2 meals) + vitamin D3 2,000-4,000 IU/day + vitamin K2 MK-7 100-180 μg/day + magnesium 300-400 mg/day + weight-bearing and resistance exercise + adequate dietary protein (1.0-1.2 g/kg/day). Reassess DEXA every 2 years. Consider pharmacologic therapy (bisphosphonate) if T-score <-2.5 develops or fragility fracture occurs.
For established osteoporosis with pharmacologic therapy: calcium 1,000-1,200 mg/day total (diet + supplementation), with supplementation typically 500-600 mg/day, plus D3 800-1,000 IU/day minimum, K2 MK-7 100-180 μg, magnesium 300-400 mg. This supports the anti-resorptive or anabolic therapy (bisphosphonate, denosumab, teriparatide, abaloparatide, romosozumab, raloxifene) per osteoporosis society guidelines.
For PPI users needing calcium: use calcium citrate 300-500 mg with each of 2 meals (does not require acid for absorption).
For prior calcium oxalate kidney stone formers: maintain adequate dietary calcium (800-1,200 mg/day) from food with meals to bind dietary oxalate; avoid supplemental calcium between meals; if supplementation required, prefer calcium citrate; increase fluid intake to maintain urine output ≥2.5 L/day; moderate dietary oxalate from high-oxalate foods.
For women in pregnancy in low-calcium-intake regions: calcium 1,500-2,000 mg/day during the second half of pregnancy for preeclampsia prevention per WHO guidance.
Advanced protocol (clinical conditions requiring specialist care). For acute symptomatic hypocalcemia: IV calcium gluconate 10% solution, 1-2 g (10-20 mL) diluted in 50-100 mL D5W over 10-20 minutes for moderate symptoms; 1 g IV push for cardiac membrane stabilization in severe hyperkalemia or hypermagnesemia. Calcium chloride 10% 500 mg-1 g is more concentrated but necrotic to soft tissue if extravasation; reserve for central line use. Continuous infusion 0.5-1 mg/kg/hour elemental calcium for sustained hypocalcemia. Correct magnesium deficiency simultaneously (often required before calcium replacement is effective).
For hypoparathyroidism (post-thyroidectomy, autoimmune): calcium carbonate or citrate 1-3 g/day elemental in divided doses + calcitriol (active vitamin D) 0.25-1 μg/day. Goal serum calcium is low-normal (8.5-9.0 mg/dL total) to minimize urinary calcium and stone risk while maintaining symptom control. Avoid overshooting to high-normal range which increases stone risk. Chronic recombinant PTH (teriparatide, abaloparatide) or PTH 1-84 (Natpara, now discontinued) is specialist therapy for refractory cases.
For chronic kidney disease with mineral bone disorder (CKD-MBD): calcium-based phosphate binders (calcium carbonate 500-1,500 mg elemental with each meal, calcium acetate 667 mg 1-3 tablets with each meal) limited by hypercalcemia and vascular calcification concerns; combine with or substitute sevelamer carbonate or lanthanum carbonate; cinacalcet for secondary hyperparathyroidism; active vitamin D analogs (calcitriol, paricalcitol, doxercalciferol) per nephrology protocols. CKD-MBD management is complex and requires nephrology specialty care.
For malignancy-associated hypercalcemia: IV bisphosphonate (zoledronate 4 mg IV, pamidronate 60-90 mg IV), IV fluids, consider denosumab 120 mg SC. Calcium supplementation is contraindicated during active hypercalcemia management.
For sarcoidosis or granulomatous hypercalcemia: calcium restriction (limit dietary calcium to minimum adequate intake), vitamin D restriction (sun avoidance plus minimal supplementation), glucocorticoids or hydroxychloroquine for inflammation control. Calcium supplementation contraindicated.
For tetany of hypomagnesemia: IV magnesium sulfate 2-4 g over 20-30 minutes (then infusion), followed by IV calcium once magnesium repleted.
Stop rules. Discontinue calcium supplementation in hypercalcemia, acute kidney stone episode during evaluation, symptomatic GI intolerance, or in patients starting ceftriaxone (formation of calcium-ceftriaxone precipitates in neonates caused FDA contraindication for co-administration in infants). New MI in patient on chronic calcium supplement at ≥1,000 mg/day: reassess supplementation necessity given Bolland cardiovascular signal. Monitor for overshoot in hypoparathyroidism management.
Commonly Stacked With
Calcium stacks logically with fat-soluble vitamins that regulate its absorption and deposition, with minerals that support bone formation and competitive absorption considerations, and with anti-resorptive drugs as adjunct therapy.
Fat-soluble vitamin core — the bone quartet. Calcium + vitamin D3 2,000-4,000 IU/day + vitamin K2 MK-7 100-180 μg/day + magnesium 300-400 mg/day is the evidence-based bone nutrition chassis. D3 drives intestinal absorption and distal tubular reabsorption; K2 carboxylates osteocalcin (driving calcium into bone matrix) and MGP (preventing vascular calcification); magnesium is cofactor for the PTH receptor, for 25-hydroxylation in liver, and for hydroxyapatite crystal structure. For postmenopausal osteoporosis prevention or management, this combination is the foundation on which anti-resorptive medication works. Skip any one element and the system is suboptimal.
Calcium + vitamin A — tension. High-dose preformed vitamin A (>3,000 μg RAE/day) in older adults is associated with increased fracture risk and can antagonize vitamin D-mediated calcium action via RXR competition. Keep vitamin A at or below RDA when using high-dose D3 for bone.
Calcium + phosphorus ratio. Dietary calcium:phosphorus ratios of approximately 1:1 to 2:1 support bone health; very high phosphorus intake (common in processed foods, colas, additives) can modestly elevate PTH and drive bone resorption over time. Dairy naturally provides roughly 1:1 Ca:P ratio. Supplemental calcium without concern for dietary phosphorus is reasonable for most.
Calcium + iron. Calcium competes with iron absorption at shared transport sites; dairy or calcium supplements with iron supplements reduce iron absorption by ~30-50%. For iron-deficient individuals (especially menstruating women), separate calcium supplements and iron supplements by several hours. Iron taken on empty stomach (or with vitamin C) and calcium with meals is a reasonable separation.
Calcium + zinc and magnesium. Very high-dose calcium (>1,500-2,000 mg/day supplemental) can modestly impair zinc and magnesium absorption. At moderate dosing (500-1,200 mg/day), the interaction is clinically minor. Many "calcium-magnesium-zinc" combination supplements deliver reasonable doses of each without problematic interaction.
Calcium + vitamin C. No adverse interaction; vitamin C does not affect calcium absorption. Calcium ascorbate is a buffered vitamin C form providing some calcium (approximately 10% by weight) with less GI acidity than ascorbic acid — useful for patients sensitive to acidic vitamin C.
Calcium + anti-osteoporosis medication. Bisphosphonates (alendronate 70 mg/week, risedronate, zoledronate IV annually), denosumab 60 mg SC every 6 months, teriparatide 20 μg SC daily, abaloparatide, romosozumab, and SERM therapy (raloxifene) are all administered alongside calcium 1,000-1,200 mg/day (dietary plus supplementation) and vitamin D 800-1,000 IU/day. This is standard practice per osteoporosis treatment guidelines. Oral bisphosphonates require 30-60 minutes separation from calcium, food, and other medications to permit absorption.
Calcium + omega-3 fatty acids + vitamin D3 + protein. Senior nutrition stack for sarcopenia and osteoporosis co-management: calcium 1,000-1,200 mg/day total, D3 2,000-4,000 IU, K2-MK7 100-180 μg, magnesium 300-400 mg, omega-3 EPA+DHA 1-2 g, protein 1.0-1.2 g/kg body weight from diet including whey or collagen supplementation, and weight-bearing exercise. Each component addresses a different facet of musculoskeletal aging.
Calcium + magnesium for muscle and cardiovascular relaxation. Some practitioners advocate calcium:magnesium supplementation at 1:1 or 2:1 ratios for smooth muscle and vascular reactivity. Mechanistically plausible; evidence for specific benefit is modest. A balanced 1:1 or 2:1 calcium:magnesium at 500-600 mg each is reasonable.
Calcium citrate vs. carbonate — choice. Calcium carbonate (40% elemental calcium by weight) requires gastric acid for dissolution and absorption; take with meals and avoid in PPI users. Calcium citrate (21% elemental calcium) is absorbed well regardless of gastric pH; preferred in PPI users, elderly with hypochlorhydria, and stone-prone patients. Citrate is slightly better absorbed per gram of supplement; citrate carries anti-stone benefit. Microcrystalline hydroxyapatite (MCHC) is bone-derived and includes collagen and trace minerals; marketing claims of superior absorption are not rigorously supported.
Calcium in protein and creatine stacking (athletic context). Creatine 5 g/day is well-tolerated with typical dietary calcium intake; no concerning interaction. Whey protein provides moderate calcium (about 200 mg per 25 g serving); factor into total daily calcium intake. Calcium and creatine have complementary roles in skeletal muscle calcium handling and phosphocreatine buffering.
Calcium with caffeine. Caffeine modestly increases urinary calcium loss; chronic high caffeine intake (>400 mg/day, equivalent to 4+ cups coffee) may contribute to negative calcium balance in those with marginal calcium intake. In practice, the effect is small if dietary calcium is adequate (about 2-3 mg additional urinary calcium loss per 100 mg caffeine).
Calcium and SGLT2 inhibitors (diabetes medication). SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) cause slight increase in serum calcium and bone turnover markers; canagliflozin specifically has an association with increased fracture risk in CANVAS trial. Ensure adequate calcium and vitamin D intake in patients on SGLT2 inhibitors.
Calcium and PPI stacking problem. Proton pump inhibitors reduce calcium carbonate absorption; for PPI users, switch to calcium citrate. PPIs also have documented association with increased fracture risk, independent of calcium absorption — relevant for prescribing duration decisions.
Calcium and corticosteroid therapy. Glucocorticoids impair calcium absorption and drive bone loss. For patients on chronic prednisone ≥5 mg/day for >3 months, calcium 1,200 mg/day + vitamin D 800-1,000 IU/day + K2 MK-7 100-180 μg + regular bone density monitoring + bisphosphonate therapy per GIOP (glucocorticoid-induced osteoporosis) guidelines.
Avoid stacking calcium with iron or thyroid medication concurrently. Space by 2-4 hours.
Side Effects & Safety
Contraindications
Calcium has well-defined contraindications and precautions based on hypercalcemia risk, renal function, cardiac context, and drug interactions. Most are dose- and context-specific. Absolute contraindications: - Hypercalcemia from any cause (primary hyperparathyroidism, malignancy, granulomatous disease, milk-alkali syndrome, sarcoidosis, vitamin D toxicity, thiazide-induced, rare genetic syndromes): supplementation is contraindicated until the underlying cause is addressed and serum calcium normalizes. - Hypercalciuria with active nephrolithiasis: supplementation between meals is contraindicated; dietary calcium with meals is protective. - Ventricular fibrillation in the absence of hyperkalemia or calcium channel blocker toxicity: calcium administration is contraindicated during VF unrelated to these specific indications. - Concurrent ceftriaxone in neonates: FDA contraindicated due to calcium-ceftriaxone precipitate formation causing fatal pulmonary and renal events. - Sarcoidosis with hypercalcemia: supplementation contraindicated; calcium restriction is part of treatment. - Williams syndrome and other genetic hypercalcemic disorders: specialist care. Relative precautions: - Chronic kidney disease: calcium supplementation and calcium-based phosphate binder use are complex and require nephrology guidance; vascular calcification risk argues for minimizing calcium load in advanced CKD. - History of calcium oxalate nephrolithiasis: supplementation with meals only, avoid between-meal dosing, consider calcium citrate over carbonate, increase fluid intake. - Coronary artery disease or high cardiovascular risk: avoid supplementation >1,000 mg/day given Bolland cardiovascular signal; prefer dietary calcium; combine with K2. - Proton pump inhibitor therapy: use calcium citrate, not carbonate (carbonate requires gastric acid). - Concurrent digitalis therapy: rapid IV calcium can potentiate digitalis toxicity and arrhythmia; give slowly and monitor. - Hypomagnesemia: correct magnesium deficiency before or concurrently with calcium replacement; hypomagnesemia impairs PTH action and blocks response to calcium. - Diuretic therapy: thiazides increase serum calcium (reduce urinary calcium); loop diuretics increase urinary calcium loss; monitor. - Bisphosphonate therapy: oral bisphosphonates must be taken on empty stomach with water only, and calcium/food separated by 30-60 minutes. - Levothyroxine: separate calcium from levothyroxine by 4 hours to prevent impaired thyroid hormone absorption. - Fluoroquinolones, tetracyclines: separate by 2-4 hours from calcium to prevent chelation and reduced antibiotic absorption. - Pregnancy: safe at RDA; avoid above UL without specific indication; WHO recommends 1.5-2 g/day in low-calcium populations for preeclampsia prevention. - Neonates and infants: individualized supplementation per pediatric guidance; avoid high-dose supplements not formulated for age. Drug-drug interactions: - Tetracyclines, fluoroquinolones + calcium: reduced antibiotic absorption, separate by 2-4 hours. - Oral bisphosphonates + calcium: reduced bisphosphonate absorption, separate by 30-60 minutes. - Levothyroxine + calcium: reduced thyroid hormone absorption, separate by 4 hours. - Iron salts + calcium: reduced iron absorption; separate by 2-4 hours or take iron on empty stomach. - Ceftriaxone + IV calcium: precipitate formation, contraindicated in neonates. - Digoxin + IV calcium: potentiated cardiac toxicity. - Thiazides + calcium supplementation: mild hypercalcemia risk; monitor serum calcium. - Lithium + calcium supplementation: lithium-induced hyperparathyroidism risk in chronic use; monitor. - SGLT2 inhibitors (canagliflozin especially) + calcium supplementation: canagliflozin has fracture risk signal; ensure calcium-vitamin D adequacy. Supplement-supplement considerations: - High-dose calcium + iron: reduced iron absorption; separate doses. - High-dose calcium + zinc and magnesium: mild reduction in zinc/magnesium absorption at very high calcium doses; clinically relevant only at >1,500-2,000 mg/day supplemental calcium. - Calcium + [vitamin D3](/compound/vitamin-d3): complementary; D3 drives calcium absorption. - Calcium + [vitamin K2](/compound/vitamin-k2): strongly complementary; K2 carboxylates osteocalcin and MGP directing calcium to bone and away from vasculature. - Calcium + [vitamin A](/compound/vitamin-a): high-dose preformed vitamin A can antagonize vitamin D-calcium biology; keep vitamin A at RDA. - Calcium + phosphorus: high phosphorus intake can modestly elevate PTH; dairy provides naturally balanced ratio. Specific patient populations. - Patients on long-term PPIs: use calcium citrate. - Patients with bariatric surgery (Roux-en-Y, sleeve gastrectomy): altered calcium absorption; follow bariatric nutrition supplement protocols, often calcium citrate 1,200-1,500 mg/day in divided doses. - Patients on corticosteroids ≥5 mg prednisone ≥3 months: calcium 1,200 mg + D3 800-1,000 IU + K2 per GIOP guidelines, plus bisphosphonate. - Patients on long-term anticonvulsants (phenytoin, carbamazepine, phenobarbital, valproate): increased vitamin D metabolism; ensure adequate calcium and D3. - Patients on GnRH agonist therapy (prostate cancer, endometriosis): bone loss risk; calcium + D3 + K2 + bisphosphonate per specialty guidelines. Overall: calcium is essential and safe at dietary and moderate supplementation doses. Avoid in hypercalcemic states, minimize high-dose supplementation given kidney stone and possible cardiovascular signals, and pay attention to drug interactions and absorption timing. Respect the integrated biology with vitamin D, K2, magnesium, and protein for bone health rather than relying on calcium alone.
Additional Notes
Calcium dosing must account for elemental calcium content (varies by salt), meal timing, vitamin D adequacy, age, sex, pregnancy status, and co-morbidity. Always read supplement labels for "elemental calcium" content, not the mass of the calcium salt.
Elemental calcium content by salt:
- Calcium carbonate: 40% elemental (1 g Tums = 400 mg elemental calcium)
- Calcium citrate: 21% elemental (1 g calcium citrate = 210 mg elemental)
- Calcium lactate: 13% elemental
- Calcium gluconate: 9% elemental
- Calcium phosphate (tricalcium): 38% elemental
- Calcium hydroxyapatite (MCHC): approximately 25-30% elemental
- Calcium glycinate (chelate): approximately 18-20% elemental
RDA and UL. Adults 19-50: 1,000 mg/day, UL 2,500 mg/day. Men 51-70: 1,000 mg, UL 2,000 mg. Women 51+ and men 71+: 1,200 mg, UL 2,000 mg. Pregnancy and lactation: 1,000 mg (14-18 years: 1,300 mg), UL 2,500 mg. Children: 700 mg (4-8 years), 1,300 mg (9-18 years). Infants AI: 200 mg (0-6 months), 260 mg (7-12 months).
Typical supplementation doses. General insurance: 500-600 mg elemental calcium per day divided into 1-2 doses with meals, only if dietary intake is inadequate. Osteoporosis therapy adjunct: 1,000-1,200 mg/day total (diet plus supplement) in combination with pharmacologic therapy. Hypoparathyroidism: 1-3 g/day elemental in divided doses, titrated to serum calcium. Preeclampsia prevention in low-intake populations: 1.5-2 g/day per WHO guideline. Renal osteodystrophy: variable, nephrology-directed, balancing calcium need with vascular calcification concern.
Absorption optimization. Absorption efficiency is highest at 500 mg or less per dose; split larger daily doses into 2-3 servings of 400-600 mg. Calcium carbonate must be taken with meals (requires gastric acid for dissolution); calcium citrate can be taken with or without meals (acid-independent absorption). PPI users: calcium citrate strongly preferred. Elderly with hypochlorhydria: calcium citrate preferred.
Bioavailability comparisons. Calcium citrate is absorbed ~22-27% from a single dose; calcium carbonate is absorbed ~22-39% with meals but variably poorly on empty stomach. Dairy calcium ~32% absorption; fortified soy milk ~24%; kale and bok choy ~45-55%; spinach <5% (oxalate binding). Calcium supplements and dairy calcium have similar retained absorption in controlled balance studies.
Timing and division. Split calcium doses away from peak iron absorption (take iron on empty stomach 2-4 hours from calcium), away from thyroid hormone (take levothyroxine on empty stomach 4 hours from calcium), and away from oral bisphosphonate (take alendronate on empty stomach with water, wait 30-60 minutes before calcium/food).
Interactions. Reduced absorption of: tetracyclines, fluoroquinolones, levothyroxine, oral bisphosphonates, iron salts. Enhanced calcium absorption: adequate vitamin D, lactose (mild effect), and fat (modest). Reduced calcium absorption: high-dose oxalates, phytates, excessive dietary fiber, PPIs (for carbonate), older age.
Special populations. Pregnancy: ensure 1,000-1,300 mg/day; standard prenatal provides 200-300 mg and diet must provide rest. Lactation: similar to pregnancy plus modest additional need for breast milk calcium. Pediatric: age-adjusted via diet; avoid supplementation above UL. Elderly: absorption efficiency declines; ensure 1,200 mg/day total with vitamin D adequacy. Fat malabsorption: not a major issue for calcium (not fat-soluble), but co-existing vitamin D deficiency impairs calcium absorption. Renal impairment: complex; nephrology-directed supplementation.
Monitoring. For routine supplementation at 500-600 mg/day, no specific monitoring required. For high-dose supplementation (>1,000 mg/day supplemental), annual serum calcium, 24-hour urinary calcium (stone risk marker; >300 mg/day in men, >250 mg/day in women is hypercalciuria), and serum creatinine. In hypoparathyroidism management, more frequent monitoring per endocrinology.
Frequently Asked Questions
What is the recommended Calcium dosage?
Dosage for Calcium varies by protocol. Consult a qualified healthcare provider.
How often should I take Calcium?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Calcium need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Calcium side effects?
Calcium has a favorable safety profile at dietary and moderate supplementation doses but carries meaningful risks at higher doses and in specific contexts. The tolerable upper intake level is 2,500 mg/day for adults 19-50 and 2,000 mg/day for adults >50; most clinical concerns emerge above 1,000-1,500 mg/day supplemental (on top of dietary intake). Kidney stones. Supplemental calcium above 1,000 mg/day, particularly when taken between meals, increases kidney stone risk. WHI 17% increased stone incidence at 1,000 mg carbonate + 400 IU D3. Dietary calcium with meals reduces stone risk by binding oxalate. Calcium citrate is less lithogenic than carbonate because citrate inhibits stone formation. Patients with prior calcium oxalate stones should limit supplementation, take what is needed with meals, and prefer citrate form. Constipation and GI effects. Calcium carbonate is a common cause of constipation at high doses; calcium citrate is less constipating. Bloating, gas, and mild nausea at 500-1,000 mg per dose are common. Doses above 1,500 mg/day frequently cause GI symptoms. Milk-alkali syndrome. Classical triad of hypercalcemia, metabolic alkalosis, and renal impairment; historically from peptic ulcer treatment with large amounts of milk plus bicarbonate. Modern version: excessive calcium carbonate antacid consumption (>10-20 g/day Tums for hypercalcemia) or calcium carbonate supplement misuse. Symptoms: headache, confusion, polyuria, renal failure, tissue calcification. Managed by discontinuation and IV fluids. Cardiovascular signal. Bolland meta-analyses suggest modest increased MI risk at supplementation ≥500 mg/day. Evidence is contested. Current pragmatic approach: limit supplementation to 500-600 mg/day where possible, prefer dietary calcium, combine with adequate [vitamin K2](/compound/vitamin-k2) to direct calcium to bone rather than vasculature. Vascular calcification in CKD. Chronic kidney disease patients have impaired phosphate clearance and altered vitamin D/PTH axis; calcium-based phosphate binders (calcium carbonate, calcium acetate) in this population can contribute to vascular calcification and are used cautiously with non-calcium binders (sevelamer, lanthanum) in advanced CKD. Dietary calcium in CKD is still needed; supplementation requires nephrology guidance. Drug interactions with absorption. Calcium chelates with tetracyclines (doxycycline, minocycline), fluoroquinolones (ciprofloxacin, levofloxacin), bisphosphonates (alendronate, risedronate, zoledronate oral forms), thyroid hormone, iron salts, and some antivirals — reducing drug absorption. Separate administration by at least 2-4 hours. Bisphosphonates specifically require ≥30-60 minutes gap before food/calcium. Levothyroxine requires 4 hours separation from calcium. PPI interaction. Long-term proton pump inhibitor therapy reduces gastric acid, which is required for calcium carbonate dissolution and ionization; calcium carbonate absorption falls in PPI users. Calcium citrate is preferred in PPI users because it does not require acidic pH for absorption. Hypercalcemia — pathologic conditions. Primary hyperparathyroidism, malignancy-associated hypercalcemia (bone metastases, tumor-secreted PTHrP), granulomatous disease (sarcoidosis, TB, fungal infections producing macrophage calcitriol), milk-alkali syndrome, thiazide-induced, vitamin D toxicity, and rare genetic syndromes (familial hypocalciuric hypercalcemia from CaSR loss-of-function mutations). Calcium supplementation is absolutely contraindicated in hypercalcemia and should be withheld until underlying cause is addressed. Hypocalcemia — recognizing deficiency. Acute symptomatic hypocalcemia presents with perioral tingling, paresthesias of fingers/toes, carpopedal spasm (Trousseau sign), facial muscle twitch on facial nerve tap (Chvostek sign), muscle cramps, and at severe levels (<6-7 mg/dL total or <3 mg/dL ionized), tetany, laryngospasm, prolonged QTc with risk of torsades de pointes, and seizures. Common causes: hypoparathyroidism (post-thyroidectomy, autoimmune), severe vitamin D deficiency, chronic kidney disease, acute pancreatitis, rhabdomyolysis, hyperphosphatemia (tumor lysis syndrome), hypomagnesemia (impairs PTH secretion and action), massive transfusion with citrated blood. Pregnancy and lactation. Calcium supplementation is safe at RDA doses. WHO recommends 1.5-2 g/day in pregnant women in low-calcium populations for preeclampsia prevention. Avoid above UL. Pediatric. Calcium supplementation for children should be age-appropriate and not exceed UL: 1,000 mg (1-3 years), 1,500 mg (4-8 years), 3,000 mg (9-13 years), 3,000 mg (14-18 years). High-dose supplementation in children is rarely needed outside specific clinical contexts. Elderly. Reduced absorption efficiency, often decreased dietary intake, frequent concurrent PPI use, and higher fracture risk make adequate calcium important. Pragmatic dose: ensure 1,000-1,200 mg/day total (dietary plus supplementation if needed) in divided doses with meals. Consider calcium citrate in PPI users. Drug-induced hypercalcemia. Thiazide diuretics reduce urinary calcium and can produce mild hypercalcemia. Lithium-induced hyperparathyroidism occurs with chronic lithium therapy. Vitamin A (retinol) toxicity can contribute to hypercalcemia via bone resorption effects. Vitamin D toxicity causes hypercalcemia by increasing intestinal absorption and bone resorption. Calcium in athletes and excessive intake in specific populations. Calcium supplementation at very high doses (>2,500 mg/day) may impair zinc, iron, and magnesium absorption through competition at shared transport sites. Male athletes routinely taking multiple-serving antacids or calcium-fortified supplements may accumulate risk; reassess total intake. Acute iatrogenic risks. IV calcium gluconate or calcium chloride rapid push can cause bradycardia, arrhythmia, and tissue extravasation injury (particularly calcium chloride, which is necrotic to soft tissue; calcium gluconate is preferred for peripheral lines). Reserve for symptomatic hypocalcemia, hyperkalemia-induced cardiac toxicity, and calcium channel blocker or magnesium toxicity reversal. Overall: at dietary and moderate supplementation doses (500-1,200 mg/day total intake), calcium is safe for most adults. High-dose supplementation (>1,500 mg/day supplemental) carries kidney stone risk, possible cardiovascular signal, and GI effects without clear incremental benefit for most populations. Specific clinical indications (osteoporosis therapy adjunct, preeclampsia prevention in deficient populations, hypoparathyroidism management, CKD-related issues) require tailored supplementation with medical guidance.
Where can I buy Calcium?
Visit our vendor directory to find trusted sources for Calcium.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
